📣 VC round data is live. Check it out!
- Public Comps
- Myriad Genetics
Myriad Genetics Valuation Multiples
Discover Myriad Genetics' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Medios, Perspective Therapeutics, Vicenne, Orthofix Medical and more.
Myriad Genetics Overview
About Myriad Genetics
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Founded
1992
HQ

Employees
2.7K
Website
Financials (LTM)
EV
$493M
Valuation Multiples
Start free trialMyriad Genetics Financials
Myriad Genetics reported last 12-month revenue of $841M and EBITDA of $38M.
In the same LTM period, Myriad Genetics generated $584M in gross profit, $38M in EBITDA, and $5M in net income.
Revenue (LTM)
Myriad Genetics P&L
In the most recent fiscal year, Myriad Genetics reported revenue of $825M and EBITDA of $39M.
Myriad Genetics is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 5%, and net margin of 1%.
Financial data powered by Morningstar, Inc.
Myriad Genetics Stock Performance
Myriad Genetics has current market cap of $406M, and enterprise value of $493M.
Market Cap Evolution
Myriad Genetics' stock price is $4.30.
Myriad Genetics share price increased by 7.5% in the last 30 days, and decreased by 19.0% in the last year.
Myriad Genetics has an EPS (earnings per share) of $0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $493M | $406M | 0.6% | 7.5% | -4.4% | -19.0% | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMyriad Genetics Valuation Multiples
Myriad Genetics trades at 0.6x EV/Revenue multiple, and 12.8x EV/EBITDA.
EV / Revenue (LTM)
Myriad Genetics Financial Valuation Multiples
As of June 3, 2026, Myriad Genetics has market cap of $406M and EV of $493M.
Myriad Genetics has a P/E ratio of 77.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Myriad Genetics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Myriad Genetics Margins & Growth Rates
Myriad Genetics grew revenue by 5% but EBITDA decreased by 3% in the last fiscal year.
In the most recent fiscal year, Myriad Genetics reported gross margin of 70%, EBITDA margin of 5%, and net margin of 1%.
Myriad Genetics Margins
Myriad Genetics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Myriad Genetics Operational KPIs
Myriad Genetics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Myriad Genetics' Rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Myriad Genetics' Rule of X is 16% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Myriad Genetics Competitors
Myriad Genetics competitors include Medios, Perspective Therapeutics, Vicenne, Orthofix Medical, Abclon, OrthoPediatrics, Coltene, TaiDoc Technology, Universal Vision and IVF hartmann.
Most Myriad Genetics public comparables operate across Diagnostics & Genomics, Laboratory Services, Medical Devices, BioTech, DeepTech and Longevity.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.3x | 0.2x | 7.5x | 5.4x | |||
| 162.7x | 213.0x | (1.4x) | (1.2x) | |||
| 2.9x | - | 12.6x | - | |||
| 0.7x | 0.6x | 6.4x | 6.2x | |||
| 130.0x | - | (37.5x) | - | |||
| 2.0x | 1.9x | 32.8x | 25.2x | |||
| 1.3x | 1.4x | 11.4x | 11.1x | |||
| 1.8x | - | 4.1x | - | |||
This data is available for Pro users. Sign up to see all Myriad Genetics competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Myriad Genetics
Myriad Genetics has acquired 6 companies to date.
Last acquisition by Myriad Genetics was on November 1st 2022. Myriad Genetics acquired Gateway Genomics for $110M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Myriad Genetics
| Description | Gateway Genomics is a biotechnology company developing non-invasive prenatal tests using cell-free fetal DNA. Based in San Diego, California, it commercializes SneakPeek Early Gender DNA Test, available from 6 weeks gestation with 99.9% accuracy validated in clinical studies. The company processes over 1 million tests annually through its CLIA-certified lab, shipping kits directly to consumers and clinics across the US. Founded in 2013, Gateway Genomics partners with major retailers like Walmart for at-home testing kits. | Counsyl is a health technology company providing DNA screening services. Based in South San Francisco, it operates a CLIA-certified laboratory for reproductive, pregnancy, and cancer tests. The platform serves patients and healthcare providers nationwide with real-time result reporting. | AssureRx Health is a personalized medicine provider offering genetic testing through the GeneSight assay to guide medication selection for behavioral health and chronic pain treatments. Clinicians use its pharmacogenomic reports to match patients with antidepressants, antipsychotics, and analgesics based on DNA analysis. The Mason, Ohio-based company partners with healthcare providers to improve outcomes in psychiatry and neurology. | Sividon Diagnostics is a Cologne-based developer of companion diagnostics for oncology. Spun out from Siemens Healthcare Diagnostics, the company enhances molecular tests for breast cancer and other malignancies to support individualized treatment decisions. Sividon leverages an international network of experts and holds intellectual property rights dating back to 2004 in molecular diagnostics. Its scientists and managers focus on evidence-based assays integrated into clinical workflows across Europe. | |
| HQ Country | |||||
| HQ City | Montpellier | San Francisco, CA | Cincinnati, OH | Hamburg | |
| Deal Date | 1 Nov 2022 | 28 May 2018 | 3 Aug 2016 | 31 May 2016 | |
| Valuation | $110M | $375M | $225M | $39M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Myriad Genetics acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Myriad Genetics
Myriad Genetics has invested in 1 company to date.
Latest investment by Myriad Genetics was on April 29th 2013. Myriad Genetics invested in RainDance Technologies in their $20M Series E round (EV/Revenue multiple available to Pro users).
Latest Investments by Myriad Genetics
| Description | RainDance Technologies is a medical technology firm specializing in droplet digital PCR platforms for life sciences research. Solutions support non-invasive liquid biopsies, single-cell analysis, molecule detection, and mutation identification in cancer studies. Services extend to diagnostics and reaction methodologies. Acquired by Bio-Rad Laboratories in 2016 and headquartered in Lexington, Massachusetts, the technology advances precision medicine applications in oncology and genomics. |
| HQ Country | |
| HQ City | Lowell, MA |
| Deal Date | 29 Apr 2013 |
| Round | Series E |
| Raised | $20M |
| Investors | Acadia Woods Partners; Alloy Ventures; Mohr Davidow Ventures; Myriad Genetics; Quaker BioVentures; Sectoral Asset Management |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Myriad Genetics investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Myriad Genetics
| When was Myriad Genetics founded? | Myriad Genetics was founded in 1992. |
| Where is Myriad Genetics headquartered? | Myriad Genetics is headquartered in United States. |
| How many employees does Myriad Genetics have? | As of today, Myriad Genetics has over 2K employees. |
| Who is the CEO of Myriad Genetics? | Myriad Genetics' CEO is Samraat S. Raha. |
| Is Myriad Genetics publicly listed? | Yes, Myriad Genetics is a public company listed on Nasdaq. |
| What is the stock symbol of Myriad Genetics? | Myriad Genetics trades under MYGN ticker. |
| When did Myriad Genetics go public? | Myriad Genetics went public in 1995. |
| Who are competitors of Myriad Genetics? | Myriad Genetics main competitors include Medios, Perspective Therapeutics, Vicenne, Orthofix Medical, Abclon, OrthoPediatrics, Coltene, TaiDoc Technology, Universal Vision, IVF hartmann. |
| What is the current market cap of Myriad Genetics? | Myriad Genetics' current market cap is $406M. |
| What is the current revenue of Myriad Genetics? | Myriad Genetics' last 12 months revenue is $841M. |
| What is the current revenue growth of Myriad Genetics? | Myriad Genetics revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Myriad Genetics? | Current revenue multiple of Myriad Genetics is 0.6x. |
| What is the current EBITDA of Myriad Genetics? | Myriad Genetics' last 12 months EBITDA is $38M. |
| What is Myriad Genetics' EBITDA margin? | Myriad Genetics' last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Myriad Genetics? | Current EBITDA multiple of Myriad Genetics is 12.8x. |
| How many companies Myriad Genetics has acquired to date? | As of June 2026, Myriad Genetics has acquired 6 companies. |
| What was the largest acquisition by Myriad Genetics? | $375M acquisition of Counsyl on 28th May 2018 was the largest M&A Myriad Genetics has done to date. |
| What companies Myriad Genetics acquired? | Myriad Genetics acquired Counsyl, Crescendo Bioscience, Assurerx Health, Gateway Genomics, Sividon Diagnostics, and Privatklinik Dr. Robert Schindlbeck. |
| In how many companies Myriad Genetics has invested to date? | As of June 2026, Myriad Genetics has invested in 1 company. |
| What was the last Myriad Genetics investment? | On 29th April 2013 Myriad Genetics invested in RainDance Technologies, participating in a $20M Series E round, alongside Acadia Woods Partners, Alloy Ventures, Mohr Davidow Ventures, Quaker BioVentures, and Sectoral Asset Management. |
| In what companies Myriad Genetics invested in? | Myriad Genetics invested in RainDance Technologies. |
See public comps similar to Myriad Genetics
Lists including Myriad Genetics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


